SRPK2 and cancer: Similarly, SRPK2 inhibition and/or dual inhibition of mTOR and O‐linked β‐N‐acetylglucosamine (O‐GlcNAc) in metabolic syndromes or cancer cells dependent on upregulated lipid metabolism has been proposed as a potential anti‐cancer therapy [288, 307].